Evidence map›Paper›PMID 26169177›Full record

ArticleBMC genomics2015

A semi-supervised approach uncovers thousands of intragenic enhancers differentially activated in human cells.

Juan González-Vallinas, Amadís Pagès, Babita Singh, Eduardo Eyras

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. The enhancer RNABlood · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Juan González-VallinasUniversitat Pompeu Fabra, Dr Aiguader 88, E08003, Barcelona, Spain. juanramongvallinas@gmail.com.
Amadís PagèsUniversitat Pompeu Fabra, Dr Aiguader 88, E08003, Barcelona, Spain. amadis.pages@upf.edu.
Babita SinghUniversitat Pompeu Fabra, Dr Aiguader 88, E08003, Barcelona, Spain. babita.singh@upf.edu.
Eduardo EyrasUniversitat Pompeu Fabra, Dr Aiguader 88, E08003, Barcelona, Spain. eduardo.eyras@upf.edu.
Pompeu Fabra University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranscriptional enhancers are generally known to regulate gene transcription from afar. Their activation involves a series of changes in chromatin marks and recruitment of protein factors. These enhancers may also occur inside genes, but how many may be active in human cells and their effects on the regulation of the host gene remains unclear.

resultsWe describe a novel semi-supervised method based on the relative enrichment of chromatin signals between 2 conditions to predict active enhancers. We applied this method to the tumoral K562 and the normal GM12878 cell lines to predict enhancers that are differentially active in one cell type. These predictions show enhancer-like properties according to positional distribution, correlation with gene expression and production of enhancer RNAs. Using this model, we predict 10,365 and 9777 intragenic active enhancers in K562 and GM12878, respectively, and relate the differential activation of these enhancers to expression and splicing differences of the host genes.

conclusionsWe propose that the activation or silencing of intragenic transcriptional enhancers modulate the regulation of the host gene by means of a local change of the chromatin and the recruitment of enhancer-related factors that may interact with the RNA directly or through the interaction with RNA binding proteins. Predicted enhancers are available at http://regulatorygenomics.upf.edu/Projects/enhancers.html .

Indexed as

Enhancer Elements, GeneticGene Expression RegulationCell Line, TumorChromatinHistonesHumansRNARNA-Binding ProteinsTranscription FactorsChromatinHistonesRNARNA-Binding ProteinsTranscription Factors

Identifiers

PMID26169177
PMCPMC4501197
OpenAlexW1778322195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.